Clinical data | |
---|---|
Routes of administration | intravenous (?) |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C36H39NO5 |
Molar mass | 565.710 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.
Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation. [1]
Clinical data | |
---|---|
Routes of administration | intravenous (?) |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C36H39NO5 |
Molar mass | 565.710 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.
Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation. [1]